SEC Form 3 · accession 0000899243-19-006445

scPharmaceuticals Inc. · SCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Feb 28, 2019

Accepted (ET)

Mar 6, 2019 · 4:31 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604950

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	13,850	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$1.66	holding	—	—	—	—	Sep 17, 2024	Common Stock	10,455	—	D
Stock Option (Right to Buy)^F3	$8.12	holding	—	—	—	—	Mar 13, 2025	Common Stock	10,455	—	D
Stock Option (Right to Buy)^F4	$3.81	holding	—	—	—	—	Apr 17, 2027	Common Stock	6,426	—	D
Stock Option (Right to Buy)^F5	$12.23	holding	—	—	—	—	Jan 17, 2028	Common Stock	17,000	—	D
Stock Option (Right to Buy)^F6	$4.88	holding	—	—	—	—	Jul 17, 2028	Common Stock	13,850	—	D

F1Consists of a restricted stock unit award made pursuant to the scPharmaceuticals Inc. 2017 Stock Option and Incentive Plan. The restricted stock units vest in equal annual installments over a two-year period beginning on February 25, 2019. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in no event later than two and one-half months after the end of the year in which such vesting date occurs.
F2This option is fully vested.
F325% of these shares vested on March 13, 2016 then in 36 equal monthly installments thereafter.
F425% of these shares vested on April 17, 2018 then in 36 equal monthly installments thereafter.
F525% of these shares vested on January 17, 2019 then in 36 equal monthly installments thereafter.
F625% of these shares shall vest on July 17, 2019 then in 36 equal monthly installments thereafter.

SVP, Finance; Principal Accounting Officer Exhibit 24 - Power of Attorney